Letter to the Editor

Fevipiprant, a selective prostaglandin D₂ receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function

Supported by a research grant to G.O. and L.X. from Novartis administered through the University of Oxford. The views expressed are those of the authors and not necessarily those of the National Health Service, the National Institute of Health Research (NIHR), or the Department of Health.

Disclosure of potential conflict of interest: I. D. Pavord has received speaker's honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, and GlaxoSmithKline and payments for organizing educational events from AstraZeneca, GlaxoSmithKline, Sanofi/Regeneron, and Teva; has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva, Merck, Circassia, Chiesi, and Knopp; and received payments to support US Food and Drug Administration approval meetings from GlaxoSmithKline; has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Teva, and Chiesi; has received a grant from Chiesi to support a phase 2 clinical trial in Oxford; and was an expert witness in 2014-2105 for a patent dispute involving Astra Zeneca and Teva. V. J. Erpenbeck is a former employee of Novartis. D. A. Sandham is a current employee of Novartis. G. Ogg has received research grants and consultancies or served on advisory boards for UCB, Celgene, AnaptysBio, Sanofi/Genzyme, La Roche Posay, Orbit Discovery, Grunenthal, Evelo, Eli Lilly, and Leo. The rest of the authors declare that they have no relevant conflicts of interest.

These authors contributed equally to this work.